University of Central Florida

STARS
Honors Undergraduate Theses

UCF Theses and Dissertations

2020

Awareness of the Unaware: Anosognosia as a Comorbidity in
Mental Health Conditions
Tiffany L. Baula
University of Central Florida

Part of the Nursing Commons, and the Psychiatric and Mental Health Commons

Find similar works at: https://stars.library.ucf.edu/honorstheses
University of Central Florida Libraries http://library.ucf.edu
This Open Access is brought to you for free and open access by the UCF Theses and Dissertations at STARS. It has
been accepted for inclusion in Honors Undergraduate Theses by an authorized administrator of STARS. For more
information, please contact STARS@ucf.edu.

Recommended Citation
Baula, Tiffany L., "Awareness of the Unaware: Anosognosia as a Comorbidity in Mental Health Conditions"
(2020). Honors Undergraduate Theses. 671.
https://stars.library.ucf.edu/honorstheses/671

AWARENESS OF THE UNAWARE: ANSOGNOSIA AS A COMORBIDITY IN
MENTAL HEALTH CONDITIONS

by

TIFFANY LAUREN BAULA

A thesis submitted in partial fulfillment of the requirements
for the Honors in the Major Program in Nursing
in the College of Nursing
and in the Burnett Honors College
at the University of Central Florida
Orlando, Florida

Spring Term
2020

ABSTRACT
AWARENESS OF THE UNAWARE: ANOSOGNOSIA AS A COMORBIDITY IN MENTAL
HEALTH CONDITIONS
Integrative Literature Review
The primary purpose of this integrative review of the literature is to describe healthcare
provider’s recognition of anosognosia in individuals with comorbid mental health disorders, as a
differentiating diagnosis needing preeminent early intervention. The secondary purpose is to
examine how anosognosia influences outcomes in the population of individuals with severe
mental illness. It is expected that early recognition by clinicians and implementation of
additional interventions to address anosognosia as the most influential comorbidity of
schizophrenia, will decrease exacerbations and improve treatment and patient outcomes.
A literature review exploring clinician’s acknowledgement of anosognosia was performed using
various databases. Search terms included: Anosognosia, Lack of Insight, Denial of Illness, and
Schizophrenia. The data was conformed into tables and synthesized the relationships to identify
consistent findings as well as gaps in the current literature. Initial review of the articles retrieved
73 articles relevant to the topic and 18 articles that met inclusion criteria. The studies suggest
that mental health conditions with anosognosia have increased rates of adverse outcomes.
Anosognosia is a difficult disorder to identify. While many studies have explored the biological
basis of anosognosia, the studies performed on safety with mental illness fail to acknowledge
anosognosia as a co-morbid condition. Evaluation and clinical guidelines remain inconsistent
with research to support the need for recognition of this co-morbidity.
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INTRODUCTION
Anosognosia, or the literal translation “Without Disease Knowledge”, has commonly
been referred to as a lack of insight into one’s disease. Anosognosia has been recognized in a
broad range of health conditions such as dementia, hemiplegia, and Huntington’s Disease, but is
considered one of the cardinal clinical manifestations found in, 60-81% of all persons diagnosed
with schizophrenia (World Health Organization, 2020). In individuals with schizophrenia,
anosognosia is one of the most prevalent and influential attributes leading to adverse and
inconsistent treatment outcomes of schizophrenia, including: Noncompliance to medication
adherence, remission of psychological symptoms, impaired community function, risk of violence
to self and others, and increased frequency of involuntary commitment to an acute mental health
facility.
In addition, the federal Healthcare Cost and Utilization Project, has found schizophrenia
to be the third leading causes of hospital readmissions in the United States, only behind renal
failure and ulcerative colitis (Fingar, K.R. et al., 2017). Anosognosia is a co-morbidity that
carries heavy influence on the potential for positive outcomes in the treatment and management
of schizophrenia, yet this complex construct has not been subjected to critical scrutiny or
adequately addressed. Understanding the multifaceted phenomenon of anosognosia in the
presence of related mental health conditions can improve the identification and treatment, and
ultimate outcomes in quality of life, for people with anosognosia and co-morbid mental health
conditions.
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PROBLEM STATEMENT
Psychiatric diagnoses are typically descriptive and are subject to scrutiny based on the
clinical manifestations of the condition. There is currently no singular blood test or brain scan
that can confidently diagnose a mental illness. Psychiatric mental health clinicians perform a
series of exams and look to the DSM-V for diagnostic categories and dimensions as a pathway of
assessment for underlying psychological conditions. Anosognosia is listed as an adjuvant clinical
manifestations of schizophrenia in the DSM-V, however, at present time there is not a
standardized diagnostic screening or plan of treatment for individuals with anosognosia as a
comorbid condition with schizophrenia. This makes it exceedingly difficult to manage
individuals that have disbelief in the accuracy of their diagnosis or the day-to-day consequence
associated with their illness.
The early detection of anosognosia and the pathological nature of the early stages of
schizophrenia, are mainstay for reducing the duration of untreated psychosis. Reduction of the
time an individual spends in a state of psychosis is exceptionally important because active
psychosis is indicative of disease progression. Longer duration of untreated psychosis is
associated with more severe symptoms when admitted to an acute care facility or mental health
unit, poor prognosis, risk of violence, elevated risk for suicide, and more frequent relapses with
involuntary commitment (Dell’Osso, Glick, Baldwin, & Altamura, 2013).
At present time, reducing psychosis for the majority of individuals can only be achieved
with consistent drug therapy adherence. The concept of insight into an individual’s mental health
condition is the leading predictor of medication adherence, and primary reason for
discontinuation of antipsychotic medication (Zhou, Rosenheck, Mohamed, 2017). When
individuals do not have acceptance or acknowledgement of their illness, they are less likely to
3

seek out care or pay for drug therapy. Challenges in the care of a person with anosognosia and a
combined mental health disorders occur when the individual’s preferences or beliefs, are at odds
with the standard of care for their primary condition. Once correlations between anosognosia and
poor treatment outcomes are established, clinician’s will be better prepared to implement
additional interventions to guide treatment adherence and improved physiologic and
psychological outcomes for this group of individuals.
Anosognosia is a multifaceted phenomenon and planning for an appropriate treatment
plan needs to take into account the individual's inability to recognize their illness, and failure to
construct an adaptive narrative account of the challenges posed by having a psychiatric
condition. An inability to reflect on the past and plan for the future makes the diagnosis of
anosognosia in a mental health condition a key factor when determining treatment and drug
therapy. Poor insight can directly influence difficulty in making sense of positive and negative
clinical manifestations of psychiatric conditions (Osatuke, Ciesla, Kasckow, Zisook &
Mohamed, 2008). For example, individuals with schizophrenia may have temporary delusions,
however, individuals with schizophrenia and anosognosia are more likely to preserve positive
symptoms as their reality, which can influence all decisions thereafter based off of fabricated
knowledge.
When determining an individual’s decisional capacity, three primary domains emerge as
the most important and predictive results to show functional competency and vulnerability
enhancement. The three primary domains affected by anosognosia are as follows: 1) Executive
functioning, memory, and insight, 2) Decisional capability for health care treatment and other
daily decisions involved in the comprehension of the nature of the information about the
condition, and 3) The understanding of application to one’s own condition, and the ability to
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process and critically understand the information provided (Jeste, Depp, & Palmer, 2006). People
who suffer from anosognosia will have an impaired ability to make well-informed decisions
about health care and are more likely to suffer poor outcomes such as financial loss and
increased risk for exacerbations of their mental health condition.
With contradicting evidence and a complex history, anosognosia is currently measured
and treated as a multifactorial anomaly that stems from psychological, neuropsychological, and
organic components. Increased admissions to acute care facilities, crisis stabilization units, and
correctional facilities can result from lack of recognition for this co-morbidity, resulting in under
treatment of the condition.

5

PURPOSE
The primary purpose of this integrative review of the literature is to examine how
anosognosia influences outcomes in the population of individuals with severe mental illness. The
secondary purpose is to describe healthcare provider’s recognition of anosognosia in individuals
with comorbid mental health disorders, as a differentiating diagnosis needing preeminent early
intervention. It is expected that early recognition by clinicians and implementation of additional
interventions to address anosognosia as the most influential comorbidity of schizophrenia, will
decrease exacerbations and improve treatment and patient outcomes.
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BACKGROUND
The investigation into anosognosia clinically requires a carefully operationalized,
working knowledge definition, as well as a systematic method of measuring and quantifying the
level of insight one has into their illness. While this remains a challenge, mental health clinicians
have defined the concept of “insight” as an individual’s ability to understand the conceptual
elements as the following: Awareness to having an illness; Recognizing the signs and symptoms
while accrediting consequences and deficit to the illness; and, The ability to appreciate and
understand the need for treatment. “Insight,” is thus recognizable as a multifactorial construct
measured on a continuum, rather than an “all or none” phenomenon (David, 1990).
Recognition of “anosognosia,” as its own terminology is not a clearly defined concept
across the mental health continuum. Little distinction has been made between anosognosia, lack
of insight, and denial of illness, as these terms have often been used interchangeably to describe
the neurological and psychological phenomena of anosognosia. The term, ’denial’, is
distinguished as a reflection of a healthy perpetual defense mechanism, rather than a pathological
avoidance of reality. The consistency and magnitude to which denial is attributed to healthy
functioning in an individual, suggests that it is a psychological base of coping (Haan & Harder,
1992). Individuals experiencing denial have information of illness cognitively and consciously
available to them, but dismiss it in an attempt to protect against distress and preserve emotional
wellbeing. By contrast, those with anosognosia do not have the information of illness available to
them to contemplate over. More than denial, the term ‘anosognosia’ is defined as a deficit of
self-awareness related to unawareness of neurological defects regardless of compelling evidence,
adjoined with the use of confabulation to explain any threats indicating illness. It is therefore
pertinent to acknowledge that these individuals are unable to fathom their illness themselves
7

when being screened for psychiatric illness. Understanding the dissimilarity between
anosognosia and denial will not only aid in the standardization of terminology and accuracy for
future research, but will also help mental health practitioners recognize the gravity of this
diagnosis, rather than seeing it as a symptom of a larger disease.

Assessment of Anosognosia
In an attempt to quantify and measure such a complex construct, several instruments
currently exist to measure the level of insight one has into their illness. Among these various
tools, the Scale to Assess Unawareness into Mental Disorder (SUMD) is one of the most widely
used instruments taking into account the wide psychometric properties of the illness. Presented
as an interview derived from Amador’s complex model of insight, the SUMD distinguishes the
processes of awareness and attribution through a 74 piece questionnaire assessing: Awareness of
having a mental disorder, recognition of signs and symptoms and explanations of the cause of
these signs and symptoms (Amador et. Al, 1994). Consider question 2 on the SUMD, “awareness
of the achieved effects of medication.” This questions the individual’s beliefs regarding the
effects of medication and explicitly associates medication compliance with one’s level of insight.
Medication compliance is thus built in as a beneficial assumption for patients, into the very
instrument used by clinicians to assess for anosognosia. Unfortunately, although the SUMD has
proven to be the most reliable tool when assessing insight, the extensive length of this test makes
it commonly used solely in studies and not in clinical settings.
In addition to the SUMD, there are several self-administered validation tools that are
present among extensive literature such as the Beck Cognitive Insight Scale (BCIS). This exam
measures the extent to which an individual recognizes their illness and need for treatment by
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evaluating patients’ self-reflectiveness and self-certainty of their experiences. One’s selfreflectiveness includes items measuring the ability to have objectivity and openness to feedback,
and the latter measures one’s certainty about their beliefs and judgment (Beck, A.T, 2004). These
subscales are useful when determining an individual's willingness and capacity to entertain
corrective feedback about delusional beliefs and thinking. The overall estimate of the composite
cognitive insight index score is then measured taking the score of self-certainty and subtracting it
from the self-reflectiveness subscale. This index was found to significantly correlate with the
Awareness of Having a Mental Disorder item on the SUMD (Riggs, S., Grant, P., Perivoliotis,
D., & Beck, A.T., 2012).
While these are the current tools that psychiatric professionals use to determine the extent
of insight an individual has insight into their disease, the measurement tools are not purposefully
designed to thoroughly evaluate the multidimensional nature of the clinical phenomenon of
anosognosia. Development of a standardized tool to diagnose and measure anosognosia would
not only aid in clinicians identification of these individuals, but would also allow for reliability
and standardization of research results.

Theory of Organic Abnormalities as a Factor of Anosognosia
Although still in its clinical incipiency, anosognosia was originally a term coined by
renowned psychologist Joseph Babinski, with regards to a lack of insight into specifically, left
hemiplegia. The concept of anosognosia reflects on the idea that focal lesions and diffuse brain
damage caused individuals with left hemiplegia to have unawareness of the paralysis that
affected them. As expressed by Xavier Amador, individuals exhibiting poor insight into
schizophrenia remarkably parallel the same characteristics expressed by individuals with
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neurological disorders. As seen in 10-18% of stroke victims with hemiparesis, these individuals
present with a severe lack of awareness into their illness, deny illness despite conflicting
evidence, use confabulations in order to explain observations made by others, and have a
compulsion to prove their self-concept (Amador & Paul-Odouard, 2000). Since the acceptance of
this parallelism, many studies have been conducted in an attempt to examine the areas of the
brain responsible for causing impairment of insight.
Theories have often framed schizophrenia as disorder resulting from a disruption in
neural connectivity leading to impaired communication between areas of the brain. The
advancement of neuroimaging techniques have provided researchers with the ability to see an
unparalleled window into the changes of the brain seen in schizophrenia that are associated with
structural abnormalities including neutrophil loss and reduced gray matter volumes in the
prefrontal cortex. The diagnosis of schizophrenia is now accepted as a hypo-functionality of the
prefrontal cortex, which is critically responsible for short-term memory, auditory processing,
episodic memory and decision-making. Anosognosia, as a complex construct of insight and
recognition, is also mediated by brain regions at a higher hierarchical level of thought
processing. One study performed by Shad, Muddasani, and Keshavan, measured specific
prefrontal sub-regions in individuals with schizophrenia, using voxel-based morphometry, an
MRI technique used to investigate focal differences in brain anatomy. In this study, researchers
utilized the SUMD (Scale to Assess Unawareness in Mental Disorder) assessment tool to
quantify the insight function in 14 subjects, and compare their level of insight to the dorsolateral
and orbitofrontal regions in the prefrontal cortex. The findings from this study resulted in an
inverse relationship between the volume of the dorsolateral region and awareness of symptoms
(Shad et. Al, 2006). The dorsolateral region of the brain being most commonly associated with
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executive functions including: The working memory, selective attention, and selfmonitoring. The results from this study are further validated from a study performed in the
Netherlands asking 47 individuals with schizophrenia and 21 normal controls, to think about
themselves while being assessed by a functional MRI. The individuals with anosognosia showed
significantly lower activation in several areas of the brain as compared to the individuals that had
high scores of insight when assessed using the Beck Cognitive Insight Scale.
It would be ideal to merit the same neurologic disturbances for both psychiatric and
neurological individuals causing the underlying the problem of lack of insight. However, since
the biological basis of neural activity and thought processing areas of the brain are not fully
understood for individuals with anosognosia as a comorbid condition with other mental health
disorders, treatment for mental health disorders is often reactive rather than proactive, leading to
exacerbation’s of the disorder and admission to a facility.
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SIGNIFICANCE
The development of the operationalized definition of anosognosia in conjunction with
new clinical measurement tools for insight, have allowed clinicians to better recognize that
persons with severe mental illness are a heterogeneous group. A large percentage of individuals
with serious mental illnesses are able to recognize their condition, and are willing to participate
in treatment. These are the individuals that show fewer problems with substance abuse, violence,
and have the most potential for recovery. Alternatively, individuals that have anosognosia, have
presented throughout literature with poor treatment compliance, increased risks for violence and
increased risks for suicide. With the developing ability to recognize individuals with
anosognosia, additional steps should be taken to implement a standardized diagnostic tool,
classify anosognosia as a subtype diagnosis, implement early interventions, and treatments to
thereby improve safety and prevent poor outcomes.
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METHODS
For this thesis, research articles were identified, systematically analyzed, and synthesized
in order to gain a better understanding of the current literature on anosognosia in the presence of
co-morbid mental health conditions, the populations healthcare needs, and effect on individual
treatment outcomes and admissions to acute care facilities or crisis stabilizations units. Databases
that were used to search for articles included Cumulative Index to Nursing and Allied Health
Literature (CINAHL), Educational Resources Information Center (ERIC), Elton B. Stephens Co.
Host (Ebsco Host), Medical Literature On-line (Medline), and Psychological Information
Database (PsychINFO). Searches used a combination of the following terms: anosognosia, lack
of insight, denial of illness, treatment adherence, violence, suicide, hospitalization, and
schizophrenia. Inclusion criteria were peer-reviewed articles and publications written in the
English language that were available from 2000-2020. While the focus of this study is on
practices in the United States, international articles written in the English language will be
included. Exclusion criteria included articles published in a language other than English and
dates outside of the specified publication date, articles without evidence of anosognosia as a
significant comorbidity of an existing mental health disorder, and lack of evidentiary support for
admission to a facility directly due to anosognosia.
Each article will be evaluated and critiqued for relevance to the topic and its application
in individuals with anosognosia and clinical practice. Subsequently, all of the articles will be
synthesized to identify consistent findings as well as the gaps in the current literature. An
evidence table will be developed to highlight findings for each article and will be included in the
review for this thesis.
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This literature search yielded 3,902 results for the key terms “anosognosia,” “lack of
insight” and “schizophrenia.” After exclusion criteria were applied, 1,746 results articles were
eliminated. The remaining 2,156 articles were reduced again to include only the key terms
“anosognosia” and “schizophrenia” and this yielded 209 results. Another pooling of terms was
used for “anosognosia,” and “treatment” or “adherence” or “suicide” or “violence” and
“schizophrenia” yielding 73 results when exclusion criteria were applied. The remaining articles
will be reviewed for relevance and additional studies from references were included in the
literature review.
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RESULTS
Disparities in Outcomes and Need for Early Intervention
The analysis of the literature review revealed a common health-related theme among
individuals that have anosognosia, specifically, the greater potential for negative outcomes due
lack of treatment compliance. Individuals with severe mental disorders are at heightened risk for
hospitalizations, risk of violence to self or others, and suicide, either due to anosognosia or poor
treatment compliance. Each of these potential negative outcomes are examined in greater detail
in the next section of this paper.
Treatment Adherence and Insight
Among the research included in the table of evidence, six of the studies are focused
around the correlation between an individual’s level of insight, and their compliance to
prescribed treatment plans. All of these studies are similar in that they assess individuals that
have a DSM diagnosis of schizophrenia. Three of the studies: (Kamali, M., Kelly, B.D., Clarke,
M., Browne, S., Gervin, M., Kinsella, A., Lane, A., Larkin, C., O'Callaghan, E. (2006) and
(Coldham EL, Addington J, Addington D. 2002) and (Novak-Grubic, V. & Tavcar, R.
(2002) assessed the correlates of treatment adherence in patients that were admitted into an acute
care facility during their first episode of psychosis. The sample subjects of these studies were
assessed at baseline and then followed up six months, to one year later. Data collected at follow
up appointments were different for each of these three studies, however, the Positive and
Negative Symptom Severity scale (PANSS) was consistently used in order to measure the
subject’s levels of insight. (Kamali et. al, 2006) found that of the (N=60) individuals, one third
exhibited poor insight at baseline and were found to be non-adherent to medication within the
first 6 months of discharge. This study yielded similar results to (Coldham et. al, 2002), which
15

found non-adherent individuals to have significantly poorer insight at both assessments. Lastly,
the study conducted by (Novak-Grubic et. al., 2002) aimed to assess the predictors of
noncompliance and outcomes for male individuals following their first episode of psychosis.
This study concluded that lack of insight was one of the leading predictors for non-compliance to
treatment. In addition, outcomes for the treatment compliant group were notably favorable with
relapse rates significantly lower than the non-adherent group. These results should be used to
establish a strategy that emphasizes special attention paid to compliance-promoting
interventions, in order to decrease readmissions to acute care facilities.
In addition to these studies, Hassan, A.E., Elnabawy, A., Eldeeb, M., & Essa, A. (2019),
and Mohamed, S., Rosenheck, R., McEvoy, J., Swartz, M., Stroup, S., Lieberman, J.A. (2009),
further validate poor insight as the greatest predictor for lack of treatment adherence with data
collected from a combined sample size of (N=421). The study findings by Mohamed et. al,
(2009) went further to suggest that higher levels of insight are associated with lower symptom
severity, and better community function. Contrariwise, these results can infer that the overall
course of illness is highly influenced by the presence of anosognosia as a co-morbidity. Lastly,
Tessier, A., Boyer, L., Husky, M., Baylé, F., Llorca, P., & Misdrahi, D. (2017), used a crosssectional study to asses the relationships between individual’s self-reported medication
adherence, insight, and therapeutic alliances, with several other measures. Results showed that
treatment adherence can be enhanced by increasing one’s level of insight through therapeutic
alliance with a psychiatrist. Thus, continuous follow-ups and consistency with office visits would
be most beneficial for those with anosognosia to promote compliance with treatment plans and
medications.
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Overall, the studies focusing on outcomes following first episode of psychosis, can
concluded that identifying the subgroup of individuals with anosognosia can predict poor
treatment adherence behaviors in the future. The studies that were analyzed for this review
reinforce a need for specialized continuous interventions for the subtype of individuals with
anosognosia in order to promote compliance.

Negative Outcomes
The research discussed has substantial evidence to demonstrate anosognosia as a pivotal
comorbidity affecting patient’s non-adherence to treatment. However, it is crucial to recognize
the importance of remaining adherent to treatment, as adherence is the leading predictor for
determining individuals’ with mental illness’ outcomes. Four studies from the table of evidence
investigate correlations to unwanted hospitalization for individuals with schizophrenia. In a
retrospective study conducted by Weiden, Kozma, Grogg, and Locklear (2004), (N=4,325)
individuals were assessed for adherence to antipsychotic medications in relation to unwanted
admissions to psychiatric facilities. Their results yielded that individuals reporting adherence of
MPR (medication possession ratio) greater than 70% are less likely to be hospitalized, as
compared with noncompliant individuals. Overall, the risk for hospitalization increased from an
Odds Ratio of 2.81 (if non-compliant for only eleven days) to 3.96 times more likely for
hospitalization, if there is a gap in medication greater than 30 days. These results suggest that the
longer an individual goes un-medicated, the more presumable it is the individual will be
hospitalized. These results are further validated by a study conducted by Morken, Widen, and
Grawe (2008), which assess the outcomes associated with treatment adherence. Results from this
study show that non-adherence to either oral or depot antipsychotic medication, are associated
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with an Odds Ratio (OR) of 10.27 for having a psychotic relapse, and a 4.00 OR for readmission
to a hospital (Morken et al., 2008). Both Morken, et. al, and Weiden, et. al, conclude there is
nearly a four-fold chance of using hospital services if the individual is non-adherent to
medication.
Proper ability for clinicians to identify anosognosia as comorbidity and further
interventions to increase treatment adherence are paramount for potential beneficial impacts on
the mental health and criminal justice delivery systems. Ascher-Svanum, Faries, Zhu, Ernst,
Swartz, and Swanson (2006), prospectively examined the relationships between adherence with
antipsychotic medications and functional outcomes among (N=1,906) individuals with a DSMIV
diagnosis of schizophrenia. The outcomes measured included: Psychiatric hospitalizations, use of
emergency psychiatric services, arrests, violence, victimizations, poorer mental functioning,
poorer life satisfaction, greater substance use, and more alcohol-related problems. Using
interviews in six month intervals for three years, Ascher-Syanum et. al’s findings highlighted
that non-adherence in the first year significantly predicted poorer functional outcomes in the
following two years.
From these results, it can loosely be assumed that early interventions would significantly
influence the potential for positive outcomes in the individuals’ future years. Interventions to
ensure compliance in the early stages following discharge can decrease unwanted admission to
facilities, and decrease periods of time spent in psychosis. Longer durations of untreated
psychosis is associated with more severe symptoms when admitted to an acute care facility or
mental health unit, poor prognosis, risk of violence, elevated risk for suicide, and more frequent
relapses with involuntary commitment (Dell’Osso, Glick, Baldwin, & Altamura, 2013).
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Insight and Violence
Another common theme that emerged in the research was the incidences of violence
among persons with anosognosia in their severe and persistent mental illness. It is important to
note that most individuals with serious mental illness are not dangerous and more likely will be
victims of perpetrators of violent acts. Nonetheless, individuals with anosognosia are at
heightened risk for violent behavior when their symptoms remain untreated, especially with
psychosis and paranoia (Treatment Advocacy Center, 2016). Four studies from the table of
evidence examine schizophrenia and its correlation to violence as an outcome. The leading
factors contributing to violent acts being: Non-adherence to medication, as well as presence of
anosognosia. Ascher-Svanum et al. found within the measured functional outcomes, nonadherent patients were more than twice (10.8% versus 4.8%; p < 0.001) as likely to engage in
violent activities and be arrested, than the control sample of adherent patients (Ascher-Svanum
et. al, 2006). Similar measures were used by Elbogen, Van Dorn, Swanson, Swartz, and
Monahan (2006), who sampled (N=1,011) outpatients from five US cities, assessing attitude
towards medication adherence and physically assaultive behavior, over a six month time span.
The results were cross-examined using logistic regression for correlations between violence and
attitude towards perceived treatment need. Those who became physically assaultive were
significantly more likely to be non-adherent to treatment (p<0.001), more severely ill, and
abusing substances. The findings from this study provide empirical support for the assertion that
adherence to medications is associated with reduced violence in patients with severe mental
disorders.
Upon closer examination of violent acts committed by individuals with severe mental
illness, two studies from the table of evidence examine the extent to which anosognosia is a
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factor. Lincoln and Hodgins (2008), examined (N=209) individuals that had previously been
admitted to a hospital, on average, 8.5 times. A chi square test was used to test the association
between the PANSS-insight ratings and history of physically aggressive behavior, over the last
two years. Results showed that significantly more patients with low or no insight, when
compared with those with good insight, behaved aggressively in the second and third follow-up
periods (Lincoln, et. al, 2008). Consistent with these results, Buckley, Hrouda, Friedman,
Noffsinger, Resnick, and Camlin-Shingler (2004) also found that the violent individuals from
their sample group had marked deficits in insight (71% scoring 4 [moderate deficit] or more, and
12.5% scoring 7 on the PNSS, with significantly greater deficits than nonviolent patients on both
the PNSS and SUMD) (Buckley et. al, 2004). Identification of anosognosia in individuals with
schizophrenia would therefore enhance clinician’s violence risk assessment in psychiatric
practice settings.

Suicide
As the second leading cause of death in Americans aged 15-24 years old, suicide is
becoming a strong vector of concern. Not coincidentally this is the age group in which most
young people leave for college, join the military, and experience a first episode of major mental
illness. Of the suicides reported to the CDC in 2018, more than 54% of them did not have a
known mental health condition. As a preventbale cause of death, addressing the known risk
factors can help decrease the risk for suicide among individuals with serious mental illness.
These influential factors include: Depressive symptoms, substance abuse, awareness of illness,
and a history of violent behavior (Treatment Advocacy Center, 2016).
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Three studies from the table of evidence examine suicide as a negative outcome for
individuals with a potential diagnosis of anosognosia in their mental illness. Findings from a
study conducted by Verma, Srivastava, Singh, Bhatia, and Deshpande (2016), (N=175) suggest
that there is a triangular relationship between individuals with good insight, better executive
functioning, and suicide attempts at some point during the illness (Verma, et. al, 2016). While
this study suggests that individuals who lack anosognosia are more likely to commit suicide, this
study fails to incorporate the level of treatment compliance within the sample. As results from
the studies in the table of evidence have shown, treatment adherence maintains a huge influence
on outcomes. For example, a suicide and mental illness study based in Kentucky found that out
of (N=28) individuals only 2 persons who had killed themselves had evidence of their
antipsychotic medications in their blood. Therefore, 93% of the sample was left untreated or had
not been adherent with their medications (Shields, Hunsaker, & Hunsaker, 2007).
Moreover, another study taking into account the level of treatment adherence was
conducted by Barrett, Mork, Færden, Nesvåg, Agartz, Andreassen, and Melle, (2015). This study
investigated the relationship between suicidality and insight, in individuals that had been
adherent to treatment for more than 52 weeks following their first episode of psychosis. Barrett
et. al, yielded results exhibiting patients who gained insight over their first year in treatment,
were, to a lesser degree, suicidal at one year follow-up. (Barrett et. al., 2015). Overall, the status
of one’s adherence to medication poses great implications for the consequent course of illness.
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DISCUSSION AND KNOWLEDGE GAPS
The literature review supports that there is an imperative need for clinicians to recognize
and treat anosognosia as a unique co-morbidity in mental illness needing additional interventions
following clinical guidelines. An overarching finding among studies is that individuals with
anosognosia are particularly at risk for lack of treatment adherence. Without compliance to
medication, these individuals will experience increased potential for negative outcomes, such as:
Unwanted admissions to psychiatric facilities, violence, and risks for suicide. The literature
synthesis highlights the need for a standardized diagnostic tool, early intervention, as well as the
need for a contingency plan when planning treatment.
Of the literature that has been reviewed for this study, there is a lack of continuity when it
comes to evaluating the sample populations for ansogonosia, and the methods used to reevaluate
these individuals. While the use of the Positive and Negative Symptom Severity Scale (PANSS),
was the predominate tool used, only one item out of thirty in the PANSS is used to assess the
level of insight. As a tool used for measuring sensitivity to treatment changes, this tool should be
used for assessing overall responsiveness to medications, rather than assessing for, and
measuring changes in level of insight for individuals with anosognosia. The use of the PANSS
tool, rather than tools used specifically for measuring insight, such as the Scale to Assess
Unawareness in Mental Disorder (SUMD), or Beck Cognitive Insight Scale, can have
implications for the criteria and methods used in samples of future studies. Standardization of the
tool used to assess for anosognosia in individuals with schizophrenia allows for validity and
reliability when comparing research.
Throughout the literature, there was consistently a gap in treatment behavior of the
samples of individuals with anosognosia. In numerous studies the sample population was being
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monitored for adherence to medications, alternatively, some studies failed to monitor whether or
not the population was being adherent to medication regimes. This difference in the sample’s
behavior can lead to concomitants in individual outcomes. Collectively, samples should mirror
behavior in treatment adherence, in order to produce standardized results for measuring
outcomes in individuals with anosognosia.
Another issue alluded in the literature is the limited number of studies that differentiate
treatments plans for individuals with anosognosia, versus the typical treatment for someone with
schizophrenia. Clinicians should make a distinction between diagnoses, as the subtype of
schizophrenia with anosognosia, should portend non-compliance as the biggest outcome
predictor. While much of the current research has been into reactive measures to increase
treatment compliance, future research should be proactive in testing interventions increase
compliance in these individuals with anosognosia. With enough research to assume individuals
with anosognosia are more likely to have poor compliance, investigation into structured
outpatient treatment plans following discharge would be more beneficial moving forward.
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IMPLICATIONS
While there exists several tools for measuring one’s insight into their illness,
standardization of a diagnostic tool to test for anosognosia would allow clinicians to better
identify this co-morbidity in individuals with severe mental illness. In addition to improving
clinicians’ recognition of this disorder, standardization would also allow for greater reliability
and validity of research into optimal treatment plans for individuals with anosognosia. Current
research into the use of an abbreviated version of the Scale to Assess Unawareness in Mental
Disorder (SUMD) shows promising results as a dependable tool to be used in clinical practice
when identifying anosognosia as a co-morbidity. As a recognized diagnosis with heavy influence
on re-hospitalization, violence, and suicide, clinicians should reclassify patients with
anosognosia into a high-risk category following evaluation.
Unsurprisingly, lack of fully developed clinical guidelines for anosognosia as a
comorbidity in mental illness, can be rationalized by the absence of a standardized diagnostic
tool. Currently, clinical practice guidelines exist within medicine to serve as a framework for
clinical decisions and support the best evidence based practices for improved patient outcomes.
The American Psychiatric Association failed to acknowledge anosognosia as a comorbid
condition in the Practice Guideline (December 2019) for Treatment of Patients with
Schizophrenia as well as the Practice Guideline (August 2015) for Psychiatric Evaluation
(American Psychiatric Association, 2020). Currently, Treatment Guidelines from the American
Psychiatric Association project to be updated in the Summer of 2020. This update should include
anosognosia as a potential comorbidity, and should be included in the initial evaluation of all
individuals with a potential diagnosis of schizophrenia. The required screening for anosognosia
during the first evaluation would require the clinician to subtype the diagnosis of schizophrenia
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as “with/without anosognosia”. Such a requirement would drastically change treatment plans and
hospital discharge plans, allowing for advanced planning and tailored treatment regimes for these
individuals.
As a high-risk category of individuals, additional measures should be taken to ensure that
they are compliant to medication and treatment regimes. In our current health care system in
America medical decisions are based off of liberty and autonomy. Just as all Americans, people
living with mental health conditions have the right to make decisions about their lives, including
their medical treatments. In a system that governs psychiatric patients through their freedom of
will, the logic of anosognosia introduces the intractable dilemma: Can a person make an
informed choice to refuse treatment, if the symptoms of the illness impair awareness of the
illness itself? This durable link between psychiatry and the law must align with a common
understanding of anosognosia and it’s relation to compliance behaviors.
It is estimated that schizophrenia only affects 1.1% of the population in the United States
of America. Despite this relatively low prevalence, schizophrenia is associated with substantial
economic burden in the United States. Tax payer’s estimated economic costs to manage
individuals with schizophrenia totaled to over $155.7 billion in 2013 (Cloutier, et. al, 2016). This
total equivalates an average excess annual cost of over $44,733 per person with schizophrenia. In
comparison, at a cost of $327 billion dollars annually to manage an estimated 88 million adults
with pre-diabetes, diabetes has become the most expensive chronic disease in the U.S (American
Diabetes Association, 2020). Nevertheless, the overall economic burden to manage an individual
with schizophrenia is more than twice the cost to manage an individual with diabetes annually.
With high expenses, investigations into the driving forces of expenses for individuals with
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Schizophrenia, are needed in order to target areas of focus for treating these individuals more
effectively.
Since it is not uncommon that individuals with anosognosia will resist treatment, a
structured environment with monitoring is needed to ensure compliance to medications. Of the
studies that have tested, certain interventions such as Mandatory Outpatient Treatment is noted to
have positive effects on individuals with anosognosia that have resisted treatment. Up to 75% of
individuals with this court order have said MOT has helped them regain control of their lives,
81% have said that MOT helped them get and stay well, and 90% of individuals have said MOT
has made them more likely to keep appointments and take medication (Treatment Advocacy
Center, 2020). With repeated results of improvement with adherence and positive outcomes,
MOT should become a guideline for treating individuals with anosognosia.
Anosognosia is a common comorbidity in schizophrenia and should be evaluated by all
clinicians. With the ability to promote better patient outcomes through early recognition of this
comorbidity, the inclusion of anosognosia should be included into the American Psychiatric
Association’s clinical guidelines and evaluations for patients with schizophrenia. It can be
loosely correlated that early recognition of this disorder will allow for reduced hospitalizations,
increased treatment adherence, and decreased risks of violence to self and others. Research into
the best proactive treatment measures is increasingly important for potentially good outcomes,
and should be the focus of future research. Successful efforts should permit early disease
recognition with aggressive and structured treatment programs.
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medication.

This study
aimed to assess
predictors of

The patients
were
clinically
stable at
study entry
and had less
than 2 years
duration of
psychotic
symptoms.
Outcomes
for poor and
good
adherence
were
compared
over a 24month
follow-up
period.

Registration
of
antipsychotic
medication
adherence
was based on
patient
interviews.
These were
done
bymonthly
for two
years.
Information
on adherence
was also
gathered
from
therapists,
carers,
plasma
assays, and
patient
records.

Good
adherence to
antipsychotic
medication
was defined
as less than
one month
without
medication.

The Odds
Ratio (OR)
of having a
psychotic
relapse was
10.27 and the
OR of being
admitted to
hospital was
4.00 among
non-adherent
patients.

Global
Assessment
of
Functioning
(GAF)
assessed
overall
functioning
at 0, 12 and
24 months.

N=56

1 year
follow up
from
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Insight was
measured
using the

Outcomes
were

Thirty
patients
(53.6%)

of noncompliance
in males with
firstepisode schizop
hrenia,
schizophreniform
and
schizoaffective
disorder. Eur
Psychiatry, 17,
148
154.

noncompliance
in male patients
with firstepisode
schizophrenia,
schizophrenifor
m and
schizoaffective
disorder in a
naturalistic
setting.

discharge of
psychiatric
facility

PNSS

measured
with
attendance of
appointments
and
medication
compliance
assessed as
self-report
and/or reports
from keyrelatives

dropped out
of treatment
in the first
year and 21
of them
relapsed.
With the Cox
survival
analysis
three
predictors of
noncomplian
ce were
found:
diagnosis of
schizophreni
a versus the
other two
diagnoses,
positive
symptoms at
admission,
and lack of
insight at
discharge.
In compliant
patients, the
relapse rate
was low, and
therefore
special
attention and
compliancepromoting
interventions
in firstepisode
patients are
needed.
Limitations:
many
patients
withdrew
from the
study, the
reasons why,
were not
listed here.
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Shad MU,
Muddasani S,
Keshavan MS.
(2006). Prefrontal
subregions and
dimension of
insight in first
episode
schizophrenia: a
pilot study.
Psychiatry Res,
146(1), 35–42.

This study
examined the
relationship
between specific
prefrontal subregions and the
awareness and
attributional
dimensions of
insight in
schizophrenia.
This study
examined the
correlation
between insight
dimensions of
awareness and
attribution of
symptoms and
dorsolateral
prefrontal cortex
(DLPFC) and
orbitofrontal
cortex (OFC)
volume

n=35

Subjects
were
determined
to have
schizophreni
a by
diagnosis
through the
DSM.

14 subjects
with firstepisode,
antipsychotic
-naïve
(FEAN)
schizophreni
a. In
addition, 21
healthy
subjects
provided
control data
for
volumetric
assessments

Insight was
assessed with
Scale to
Assess
Unawareness
of Mental
Disorders.
Morphometri
c
assessments
were
adjusted for
intra-cranial
volume and
were
conducted by
trained raters
blind to
clinical
information
using
BRAINS-2.

The findings
from this
study
resulted in an
inverse
relationship
between the
volume of
the
dorsolateral
region and
awareness of
symptoms.
The
dorsolateral
region of the
brain being
most
commonly
associated
with
executive
functions
including:
The working
memory,
selective
attention, and
selfmonitoring.
Limitations:
The sample
size in this
study is
small.

Tessier, A.,
Boyer, L., Husky,
M., Baylé, F.,
Llorca, P., &
Misdrahi, D.
(2017).
“Medication
adherence in
schizophrenia:
The role of
insight,
therapeutic
alliance and
perceived trauma
associated with
psychiatric care.”

Cohort study
assessed the
relationship reg
arding
symptomatolog
y, self-reported
adherence with
medication,
insight,
medication sideeffects,
therapeutic
alliance and
perceived
trauma related

n=72

a diagnosis
of
schizophreni
a or
schizoaffecti
ve disorder
according to
DSM-IVTR criteria
(2) at least
18 years old,
(3) able to
understand
the protocol,
and (4)
fluent
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The severity
of one’s
insight and
psychopathol
ogy was
assessed by
the PANSS,
which
comprises
three
different
subscales
(positive,
negative and
general
psychopathol

Adherence to
medication
was selfreported.

Medication
nonadherence
concerns
50% of
schizophreni
c patients.
Adherence
could be
enhanced by
reducing
perceived
trauma or
increasing
insight.

Psychiatry
Research, 257,
315-321.

to psychiatric
treatment.

French
speaker.
Exclusion
criteria
included
traumatic
head injury,
any past or
present
major
medical or
neurological
illness and
mental
retardation.

ogy).
The present
study
articulates
the need for
mental health
clinicians to
be sensitive
to patients'
perception of
traumatic
experiences
related to
psychiatric
treatment
and to be
aware of the
importance
of
therapeutic
relationship
in treating
patients with
schizophreni
a.
Limitations:
As this
assessment
reflected the
endorsement
of a single
item, it may
have been
subject to
recall bias or
influenced
by the
participant's
mental state.
Third, insight
was
evaluated
using the BIS
scale
(Birchwood
et al., 1994).
This selfreport insight
scale (BIS) is
a quick and
reliable
measure
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exploring
insight in a
multidimensi
onal concept
which
include the
subjective
impression
of patient
facing to
clinical
symptoms.
Van der Meer, L.,
De Vos, A.E.,
Stiekema, A.P.,
Pijnenborg, G.H.,
Van Tol, M.J.,
Nolen, W.A.,
David, A.S., &
Aleman, A.
(2013). Insight in
schizophrenia:
Involvement of
self-reflection
networks?
Schizophrenia
Bulletin, 39(6),
1288—1295.

The current
study aims to
investigate the
neural correlates
of self-reflective
processing and
its relationship
with insight in
schizophrenia.

N=47
(shizo).
N=21
(controls)

Forty-seven
schizophreni
a patients
and 21
healthy
controls
performed a
selfreflection
task in a
functional
magnetic
resonance
imaging
(fMRI)
scanner. The
tasks
comprised a
selfreflection,
close otherreflection,
and a
semantic
(baseline)
condition.
Insight
scores were
obtained
with the
(Beck
Cognitive
Insight
Scale
[BCIS]).
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A total of 47
patients with
a diagnosis
of
schizophreni
a participated
in the study
(35 male, 12
female).
Patients were
inpatients as
well as
outpatients,
and were
recruited
from several
mental health
institutions in
the North of
the
Netherlands.
Clinicians
screened
their
caseload and
selected
patients
based on
three
questions of
the
multidimensi
onal
construct of
insight to
estimate
insight level
and to ensure
that both
patients with

In the
scanner, task
instructions
were once
more
presented on
the screen.
The selfreflection
task
contained
180
sentences,
subdivided
into three
main
conditions
(self, other,
and
semantic) of
60 sentences
each. Total
task duration
was 15
minutes
long.

Better insight
was
associated
with greater
response in
the inferior
frontal gyrus,
anterior
insula, and
inferior
parietal
lobule during
selfreflection. In
addition,
better
cognitive
insight was
associated
with higher
activation in
ventromedial
prefrontal
cortex during
selfreflection.

good and
with poor
insight would
be selected.
Verma, D.,
Srivastava, M.K.,
Singh, S.K.,
Bhatia, T. &
Deshpande, S.N.
(2016). Lifetime
suicide intent,
executive
function and
insight in
schizophrenia and
schizoaffective
disorders.
Schizophr. Res.,
178, 12–16.

This study was
investigating the
triangular
relationship
between suicide
intent, insight
and cognitive
competence in
schizophrenia.

N=175

Weiden, P.,
Kozma, C.,
Grogg, A. &
Locklear, J.
(2004). Partial
compliance and
risk
of rehospitaliza
tion among
California
Medicaid patients
with
schizophrenia.
Psychiatr
Serv
55,
886–891.

Retrospective
Study
The objective of
this study was to
evaluate the
relationship
between
compliance with
an antipsychotic
medication
regimen and
risk of
hospitalization
in a cohort of
California
Medicaid
patients with
schizophrenia.

N=4,325
Outpatients
for whom
antipsychoti
cs were
prescribed
for treatment
of
schizophreni
a from 1999
to 2001.

DSM-IV TR
diagnoses of
schizophreni
a or
schizoaffecti
ve disorder

All the
subjects
were
interviewed
on Beck's
cognitive
insight scale
and tested
on the Trail
Making
Test. All the
subjects
who had
lifetime
history of
suicide
attempt
were
interviewed
on Pierce's
suicide
intent scale.

All the
subjects were
interviewed
on Beck's
cognitive
insight scale
and tested on
the Trail
Making Test.
All the
subjects who
had lifetime
history of
suicide
attempt were
interviewed
on Pierce's
suicide intent
scale.

N/A

Our study
suggests that
good insight
and better
executive
functioning
may be
significantly
correlated
with suicide
attempts at
some time
during the
course of
illness.

Patients
were
followed for
one year and
had an
average of
19.1
dispensing
events.

DSM dx of
schizophreni
a.

Compliance
behavior was
estimated by
using four
different
definitions:
gaps in
medication
therapy,
medication
consistency
and
persistence,
and a
medication
possession
ratio.

Risk of
hospitalizatio
n was
significantly
correlated
with
compliance.
With all
definitions,
lower
compliance
was
associated
with a
greater risk
of
hospitalizatio
n over and
above any
other risk
factors for
hospitalizatio
n. A gap of
11 to 30 days
was
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patients were
also required
to have at
least one
prescription
in the six
months
before their
index date.

associated
with an OR
of 2.81, and
a gap of
more than 30
days was
associated
with an OR
of 3.96.
Limitations:
This study
did not take
into account
the risk
factor of lack
of insight for
these
patients
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